6-K 1 d892796d6k.htm 6-K 6-K

UNITED STATES SECURITIES

AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the Month of April 2020

Commission File Number: 001-38281

ERYTECH Pharma S.A.

(Translation of registrant’s name into English)

 

 

60 Avenue Rockefeller

69008 Lyon France

(Address of principal executive office)

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

☒ Form 20-F         ☐ Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐


 

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

Press Release

On April 28, 2020, Ertech Pharma, Inc. (the “Company”) issued a press release announcing that the U.S. Food and Drug Administration has granted the Company Fast Track designation for eryaspase as a second-line treatment for metastatic pancreatic cancer. A copy of the press release is attached to this Report on Form 6-K as Exhibit 99.1.

EXHIBITS

 

Exhibit

  

Description

99.1    Press Release dated April 28, 2020.


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

   

ERYTECH Pharma S.A.

Date: April 30, 2020     By:   /s/ Eric Soyer
      Name: Eric Soyer
      Title: Chief Financial Officer and Chief Operating Officer